| The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services DGR Evans, J Barwell, DM Eccles, A Collins, L Izatt, C Jacobs, ... Breast Cancer Research 16 (5), 1-6, 2014 | 369 | 2014 |
| The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation C Black, C Clar, R Henderson, C MacEachern, P McNamee, Z Quayyum, ... NIHR Health Technology Assessment programme: Executive Summaries, 2009 | 352 | 2009 |
| Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non–small-cell lung cancer SS Ramalingam, ML Maitland, P Frankel, AE Argiris, M Koczywas, ... Journal of Clinical Oncology 28 (1), 56, 2010 | 301 | 2010 |
| Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2 R Lilenbaum, R Axelrod, S Thomas, A Dowlati, L Seigel, D Albert, K Witt, ... Journal of Clinical Oncology 26 (6), 863-869, 2008 | 230 | 2008 |
| Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study—CALGB … NE Ready, HH Pang, L Gu, GA Otterson, SP Thomas, AA Miller, ... Journal of Clinical Oncology 33 (15), 1660, 2015 | 154 | 2015 |
| Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial N Jain, E Curran, NM Iyengar, E Diaz-Flores, R Kunnavakkam, ... Clinical cancer research 20 (2), 490-498, 2014 | 129 | 2014 |
| A phase II trial of Triapine®(NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 AM Traynor, JW Lee, GK Bayer, JM Tate, SP Thomas, M Mazurczak, ... Investigational new drugs 28, 91-97, 2010 | 120 | 2010 |
| A cost-utility analysis of interferon beta for multiple sclerosis. D Parkin, P McNamee, A Jacoby, P Miller, S Thomas, D Bates Health technology assessment (Winchester, England) 2 (4), iii-54, 1998 | 108 | 1998 |
| Cancelled operations: a 7-day cohort study of planned adult inpatient surgery in 245 UK National Health Service hospitals DJN Wong, SK Harris, SR Moonesinghe, SR Moonesinghe, DJN Wong, ... British journal of anaesthesia 121 (4), 730-738, 2018 | 96 | 2018 |
| Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer SL Hines, BA Mincey, JA Sloan, SP Thomas, E Chottiner, CL Loprinzi, ... Journal of clinical oncology 27 (7), 1047, 2009 | 93 | 2009 |
| Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: Results from Intergroup Trial N9741 T Delaunoit, RM Goldberg, DJ Sargent, RF Morton, CS Fuchs, BP Findlay, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 92 | 2004 |
| Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non … RC Doebele, D Spigel, M Tehfe, S Thomas, M Reck, S Verma, J Eakle, ... Cancer 121 (6), 883-892, 2015 | 83 | 2015 |
| Placebo-controlled trial to determine the effectiveness of a urea/lactic acid–based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: north … SL Wolf, R Qin, SP Menon, KM Rowland Jr, S Thomas, R Delaune, ... Journal of clinical oncology 28 (35), 5182, 2010 | 79 | 2010 |
| Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non–small-cell lung cancer CX Ma, S Nair, S Thomas, SJ Mandrekar, DA Nikcevich, KM Rowland, ... Journal of clinical oncology 23 (25), 5929-5937, 2005 | 78 | 2005 |
| Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non–small-cell lung cancer with cyclooxygenase-2 … MJ Edelman, X Wang, L Hodgson, RT Cheney, MQ Baggstrom, ... Journal of Clinical Oncology 35 (19), 2184, 2017 | 68 | 2017 |
| Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium NP Campbell, R Kunnavakkam, N Leighl, MD Vincent, DR Gandara, ... Lung Cancer 78 (1), 76-80, 2012 | 64 | 2012 |
| A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer RT Lee, KE Beekman, M Hussain, NB Davis, JI Clark, SP Thomas, ... Clinical genitourinary cancer 6 (1), 21-24, 2008 | 55 | 2008 |
| A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non–small-cell lung cancer: North Central Cancer … Y Zhao, NR Foster, JP Meyers, SP Thomas, DW Northfelt, KM Rowland Jr, ... Journal of Thoracic Oncology 10 (1), 172-180, 2015 | 51 | 2015 |
| Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with … DVT Catenacci, N Bahary, SR Nattam, RW Marsh, JA Wallace, L Rajdev, ... Journal of Clinical Oncology 31 (15_suppl), 4012-4012, 2013 | 46 | 2013 |
| Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North … A Jatoi, SR Dakhil, NR Foster, C Ma, KM Rowland Jr, DF Moore Jr, ... Journal of thoracic oncology 3 (5), 516-520, 2008 | 42 | 2008 |
